|Bid||0.00 x 800|
|Ask||81.74 x 1800|
|Day's Range||81.67 - 82.66|
|52 Week Range||61.05 - 82.80|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||27.88|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||0.88 (1.07%)|
|1y Target Est||82.93|
President Trump's threats to ratchet up tariffs on goods from China will have a minimal impact on biotech companies, experts say. Meanwhile, medtech companies dodged tariffs in Mexico.
Baxter International Inc. (BAX), a global innovator in renal care, showcased 19 data presentations on therapy options at the 56th ERA-EDTA Congress, Budapest, Hungary, June 13-16. The presentations spanned the renal care continuum, from chronic kidney disease (CKD) management to peritoneal dialysis (PD) and hemodialysis (HD).
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Baxter International Inc. (BAX), a global innovator in renal care, today announced receipt of a major research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF)’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis (HD) option for end-stage renal disease (ESRD) patients. The grant provides €1.5 million in funding over three years to Baxter’s research team in Hechingen, Germany, and the consortium partners to find a solution that will improve health-related, quality-of-life outcomes for the millions of patients receiving HD therapy globally.
Baxter International Inc. (BAX), a leading global medical products company, will host a conference call to discuss its second quarter 2019 financial results on Thursday, July 25, 2019, at 7:30 a.m. Central Time. The Conference ID is 2089733.
DEERFIELD, Ill.-- -- Enhancements designed to give healthcare providers access to more comprehensive treatment data and improve clinic workflow New study further supports value of remote patient management technology to personalize dialysis treatments, reduce alarms and in-person visits, while saving clinicians and patients significant time Baxter International Inc. , a global innovator in renal care, ...
The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (BAX), announced today a $2.2 million grant to Operation Smile, one of the world’s largest volunteer-based surgical nonprofit organizations, to deliver free surgical and multidisciplinary care to underserved communities in India. During the next three years, the grant will support Operation Smile’s year-round care centers in Mumbai, Srinagar and Bangalore—operated in partnership with the Inga Health Foundation—along with a new care center in Durgapur, West Bengal.
Baxter International Inc. (BAX), a global leader in acute care therapies, announced today that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis. The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy this week, add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions.
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Synchrony Financial announced before the opening bell Thursday that it will increase its quarterly dividend by a penny, following dividend increases by Phillips 66 and Baxter International.
Baxter International Inc. (BAX), a leading global medical products company, today announced that representatives of the company will conduct a series of Fixed Income Investor Presentations on Thursday, May 9, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...
Baxter International Inc. (BAX), a leading global medical products company, announced today that it has been named a 2019 Best Company for Multicultural Women by Working Mother magazine. This recognition is a result of the company’s sustained focus on supporting and advancing multicultural women at all levels of the organization globally.
Baxter International Inc. , a leading global medical products company, today announced an increase in the company’s quarterly cash dividend, to a rate of $0.22 per share of common stock.
Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $673 million over the last one-month into ETFs that hold BAX are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. BAX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Baxter International Inc. (BAX), a leading global medical products company, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.
Baxter International Inc. (BAX), a global leader in renal care, along with the National Association for the Advancement of Colored People (NAACP) and the Alliance for Home Dialysis, today announced that the Dialysis Health Imperative for Access, Choice, and Equity (ACE) program will be expanded for a third year. This year, the program is expected to reach even more individuals and focus on driving awareness of kidney disease—including risk factors, prevention strategies and home dialysis treatment options—among the African American community.
Higher revenues, growth in APAC and strong operating margin benefit Baxter's (BAX) Q1 earnings. However, weak performance at Medication Delivery and Clinical Nutrition remains a concern.